Sanofi (NASDAQ:SNY - Get Free Report)'s share price gapped down before the market opened on Friday . The stock had previously closed at $52.35, but opened at $49.91. Sanofi shares last traded at $49.24, with a volume of 1,248,348 shares changing hands.
Wall Street Analyst Weigh In
SNY has been the subject of a number of research analyst reports. The Goldman Sachs Group began coverage on shares of Sanofi in a research note on Friday, March 21st. They issued a "neutral" rating and a $65.00 price target for the company. BNP Paribas assumed coverage on shares of Sanofi in a report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective for the company. Finally, Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $63.33.
Check Out Our Latest Stock Analysis on Sanofi
Sanofi Trading Down 5.6%
The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The business's fifty day simple moving average is $52.25 and its 200 day simple moving average is $51.92. The stock has a market cap of $121.15 billion, a price-to-earnings ratio of 19.84, a P/E/G ratio of 1.01 and a beta of 0.55.
Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, beating analysts' consensus estimates of $0.90 by $0.04. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The business had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. During the same quarter in the prior year, the firm earned $1.78 EPS. The company's revenue for the quarter was down 11.0% compared to the same quarter last year. On average, research analysts predict that Sanofi will post 4.36 EPS for the current year.
Sanofi Increases Dividend
The business also recently declared an annual dividend, which will be paid on Thursday, June 12th. Stockholders of record on Friday, May 9th will be given a dividend of $2.0369 per share. This represents a dividend yield of 3.1%. This is a boost from Sanofi's previous annual dividend of $1.48. The ex-dividend date of this dividend is Friday, May 9th. Sanofi's dividend payout ratio is presently 57.14%.
Institutional Trading of Sanofi
Hedge funds have recently made changes to their positions in the stock. Brighton Jones LLC boosted its holdings in shares of Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock valued at $261,000 after acquiring an additional 1,869 shares during the period. Synergy Asset Management LLC bought a new stake in Sanofi in the 4th quarter valued at about $25,000. OLD National Bancorp IN boosted its stake in Sanofi by 12.9% during the 4th quarter. OLD National Bancorp IN now owns 24,373 shares of the company's stock valued at $1,176,000 after purchasing an additional 2,790 shares during the period. Cibc World Market Inc. grew its position in Sanofi by 3.4% in the 4th quarter. Cibc World Market Inc. now owns 315,888 shares of the company's stock worth $15,235,000 after purchasing an additional 10,328 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in Sanofi by 13.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 63,845 shares of the company's stock worth $3,079,000 after purchasing an additional 7,615 shares during the last quarter. Institutional investors own 14.04% of the company's stock.
About Sanofi
(
Get Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Featured Articles
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
